1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Epiomic Epidemiology Series: Essential Thrombocythemia Forecast in 9 Major Markets 2016-2026

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Essential Thrombocythemia (ET) in 9 Major Markets

Essential Thrombocythemia (ET) or Primary Thrombocythemia, is a rare, chronic myeloproliferative disorder that involves the over production of blood platelets by the bone marrow. ET is characterized by a persisting elevated platelet count >450,000/µL, with megakaryocytic hyperplasia, and patients will likely also suffer from splenomegaly and thrombotic or hemorrhagic episodes or both.
This report provides the current prevalent population for ET across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ET have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for ET include:

• Secondary myelofibrosis
• Acute myeloid leukaemia
• Anaemia
• Splenomegaly
• Hepatomegaly
• Incident thrombosis
• Deep vein thrombosis
• Pregnancy complications

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global ET’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ET and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ET’s prevalent population.
• Identify sub-populations within ET which require treatment.
• Gain an understanding of the specific markets that have the largest number of ET patients.

Table Of Contents

Epiomic Epidemiology Series: Essential Thrombocythemia Forecast in 9 Major Markets 2016-2026
Table of Contents
- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors and Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis and Clinical Course
- Key Co-morbid Conditions/Features Associated with the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Essential Thrombocythemia
- Features of Essential Thrombocythemia Patients
o Type of Thrombotic Events
o Abnormal Organ Enlargement Associated with ET
o Blood Cell Associated Conditions
o Gene Mutations in ET
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix


List of Tables

- WHO classification criteria for ET diagnosis
- Prevalence of Essential Thrombocythemia, total (000s)
- Prevalence of Essential Thrombocythemia, males (000s)
- Prevalence of Essential Thrombocythemia, females (000s)
- Type of thrombosis in Essential Thrombocythemia patients, total (000s)
- History of thrombotic event in Essential Thrombocythemia patients, total (000s)
- Site of arterial thrombosis in Essential Thrombocythemia patients, total (000s)
- Site of venous thrombosis in Essential Thrombocythemia patients, total (000s)
- Prevalence of splenomegaly in Essential Thrombocythemia, total (000s)
- Prevalence of hepatomegaly in Essential Thrombocythemia, total (000s)
- Prevalence of myelofibrosis (SMF) in Essential Thrombocythemia, total (000s)
- Prevalence of anaemia in Essential Thrombocythemia, total (000s)
- Prevalence of JAK2 mutation in Essential Thrombocythemia patients, total (000s)
- Abbreviations and Acronyms used in the report
- USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- France Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- France Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
- India Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
- India Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    10 pages
  • Blood Disease  

    Blood Supply  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    8 pages
  • Blood Disease  

    Cytokine  

    Cancer  

  • United States  

View report >

Related Market Segments :

Blood Disease

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.